FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2144-2146 November 16, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Drüeke, T. B. Related Article by Singh, A. K.

Anemia develops in most patients with chronic kidney disease, historically often requiring transfusion, with obvious risks. With the advent of recombinant erythropoietin in the late 1980s, it became possible to treat anemia without transfusion, ushering in a new era. It soon became clear that additional considerations were important, such as ensuring adequate iron stores, providing sufficient folate and vitamin B₁₂, and identifying other conditions affecting the hemoglobin level. How best to administer erythropoietin — as well as how best to produce it, given cases of pure red-cell aplasia related to production and administration — were also identified as important . . . [Full Text of this Article]

Source Information

From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy (G.R.).

This article has been cited by other articles:

• Kazory, A., Ross, E. A. (2009). Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 53: 639-647 [Abstract] [Full Text]  
• Townsend, R. R. (2008). Stroke in Chronic Kidney Disease: Prevention and Management. CJASN 3: S11-S16 [Abstract] [Full Text]  
• Gilmartin, C. (2007). Pharmacist's role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefits. Am J Health Syst Pharm 64: S15-S22 [Abstract] [Full Text]  
• Barany, P., Muller, H.-J. (2007). Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant 22: iv10-iv18 [Abstract] [Full Text]  
• Tonks, A. (2007). Too much of a good thing. BMJ 334: 978-980 [Full Text]  
• van Veldhuisen, D. J., McMurray, J. J.V., RED-HF Executive Committee, (2007). Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 9: 110-112 [Full Text]  
• (2006). Correcting Anemia in Patients with Chronic Kidney Disease. JWatch General 2006: 1-1 [Full Text]